Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

Adebrelimab is named as a drug or biological intervention in 110 clinical trials in our China trial register, 77 of which are recruiting. Lead sponsors include Suzhou Suncadia Biopharmaceuticals Co., Ltd. (16), Shanghai Hengrui Pharmaceutical Co., Ltd. (11) and Fudan University (8). Registered phases: Phase 2, Phase 1/2, Phase 1, Phase 3, Observational, Phase 2/3, Not applicable and Phase EARLY_PHASE1. Conditions studied include Pancreatic Cancer; Esophageal Cancer; Breast Cancer.

Clinical trials of Adebrelimab

110 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT04516681	Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer, Vitamin C, GLUT3	Phase 3	Recruiting	Fudan University	China
NCT06618664	A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Advanced Hepatocellular Carcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07111832	A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer (ClinicalTrials.gov ↗) PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07679360	A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer (ClinicalTrials.gov ↗) Triple Negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06791460	Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer Recurrent	Phase 2/3	Recruiting	Obstetrics & Gynecology Hospital of Fudan University	China
NCT07454720	A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (ClinicalTrials.gov ↗) Locally Advanced Resectable Rectal Cancer	Phase 2/3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT05076682	Reverse Triple Negative Immune Resistant Breast Cancer (ClinicalTrials.gov ↗) Triple-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
NCT06091124	Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma (ClinicalTrials.gov ↗) Neuroendocrine Carcinoma of the Bladder, Bladder Cancer	Phase 2	Recruiting	RenJi Hospital	China
NCT06149130	Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Tongji Hospital	China
NCT06177925	A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC (ClinicalTrials.gov ↗) Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site	Phase 2	Recruiting	Nanfang Hospital, Southern Medical University	China
NCT06208462	Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT06261125	Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) (ClinicalTrials.gov ↗) Hepatocellular Carcinoma	Phase 2	Recruiting	Mian XI	China
NCT06266832	The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma (ClinicalTrials.gov ↗) Rectal Adenocarcinoma	Phase 2	Recruiting	Sir Run Run Shaw Hospital	China
NCT06277791	The Combination of Adebrelimab and TP Regimen for Neoadjuvant Therapy in Patients With Stage IVB Oral Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Clinical IVb Stage Oral Squamous Cell Carcinomas Patients	Phase 2	Recruiting	Hospital of Stomatology, Wuhan University	China
NCT06282445	Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer Metastatic	Phase 2	Recruiting	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	China
NCT06340230	SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer (ClinicalTrials.gov ↗) HR Positive/HER2 Low Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
NCT06349889	Adebrelimab and Chemoradiotherapy in High-risk LANPC (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma, Nasopharyngeal Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
NCT06360042	Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC (ClinicalTrials.gov ↗) Unresectable Hepatocellular Carcinoma	Phase 2	Recruiting	Peking University Cancer Hospital & Institute	China
NCT06415669	A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma (ClinicalTrials.gov ↗) Gastric/Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
NCT06424899	A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC (ClinicalTrials.gov ↗) Non Small Cell Lung Cancer	Phase 2	Recruiting	Zeng Jian	China
NCT06455410	GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma (ClinicalTrials.gov ↗) Nasopharyngeal Carcinoma	Phase 2	Recruiting	Sun Yat-sen University	China
NCT06475209	Adebrelimab + Apatinib in SCLC Maintenance Therapy (ClinicalTrials.gov ↗) SCLC	Phase 2	Recruiting	Tang-Du Hospital	China
NCT06482788	Perioperative Treatment of Resectable Adenocarcinoma of Esophagogastric Junction by Immunotherapy (Adebrelimab) Combined With Chemotherapy (XELOX): a Prospective, Single-center, Feasibility Study (ClinicalTrials.gov ↗) Esophagogastric Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
NCT06483282	A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer (ClinicalTrials.gov ↗) Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Jin Ying	China
NCT06485544	Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial (ClinicalTrials.gov ↗) Small Cell Lung Cancer (SCLC)	Phase 2	Recruiting	Tang-Du Hospital	China
NCT06500208	Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (ClinicalTrials.gov ↗) Breast Cancer	Phase 2	Recruiting	Shanghai Jiao Tong University School of Medicine	China
NCT06506292	A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) (ClinicalTrials.gov ↗) Adebrelimab (SHR-1316), XELOX, GC/GEJC	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT06510660	Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
NCT06531278	Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety (ClinicalTrials.gov ↗) Pancreatic Cancer Metastatic to Liver	Phase 2	Recruiting	Jiang Long	China
NCT06610734	Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC) (ClinicalTrials.gov ↗) Small Cell Lung Cancer Extensive Stage	Phase 2	Recruiting	Sichuan University	China
NCT06663059	Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study (ClinicalTrials.gov ↗) Esophageal Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
NCT06749730	Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma (ClinicalTrials.gov ↗) Unresectable Biliary Tract Carcinoma	Phase 2	Recruiting	Henan Cancer Hospital	China
NCT06765616	Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer (ClinicalTrials.gov ↗) Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy	Phase 2	Recruiting	Feng Tian	China
NCT06895928	A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07007364	Neoadjuvant Low-Dose Radiotherapy Combined With Adebrelimab and Single-Agent Albumin-Bound Paclitaxel Chemotherapy for Early-Stage Oral Squamous Cell Carcinoma: A Prospective, Single-Arm Clinical Trial (ClinicalTrials.gov ↗) Early-Stage Oral Squamous Cell Carcinoma	Phase 2	Recruiting	Jun Jia	China
NCT07055841	Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Squamous Cell Carcinoma of Head and Neck	Phase 2	Recruiting	Xiuping Ding	China
NCT07110571	A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07131514	HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Recruiting	Ruijin Hospital	China
NCT07135544	A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer, Biliary Tract Cancer (CCA)	Phase 2	Recruiting	Yongjun Chen	China
NCT07141264	Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy (ClinicalTrials.gov ↗) SCLC,Extensive Stage	Phase 2	Recruiting	Tang-Du Hospital	China
NCT07229729	A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07241767	A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer (ClinicalTrials.gov ↗) Lung Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd.	China
NCT07241793	Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) (ClinicalTrials.gov ↗) Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent	Phase 2	Recruiting	Sun Yat-sen University	China
NCT07268040	A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors (ClinicalTrials.gov ↗) Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07437898	Neoadjuvant Adebrelimab Plus Chemotherapy for Esophageal Cancer: A Clinical Study (ClinicalTrials.gov ↗) Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	The Affiliated Hospital of Putian University	China
NCT07457346	A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (ClinicalTrials.gov ↗) Head and Neck Cancer Squamous Cell Carcinoma	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
NCT07569679	Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Recruiting	Air Force Military Medical University, China	China
NCT07638852	Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM. (ClinicalTrials.gov ↗) TNBC, Triple Negative Breast Cancer, Brain Metastasases	Phase 2	Recruiting	Fudan University	China
NCT07668453	An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies (ClinicalTrials.gov ↗) Biliary Tract Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT07670273	Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
NCT07704177	Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
NCT07718490	Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Metastatic Colorectal Cancer	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT07731828	Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II Trial (ClinicalTrials.gov ↗) Cervical Neoplasms	Phase 2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
NCT07733830	Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC (ClinicalTrials.gov ↗) Esophageal Cancer	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT07770113	A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer (ClinicalTrials.gov ↗) GC/GEJC	Phase 2	Recruiting	The First Affiliated Hospital of Zhengzhou University	China
NCT06222879	Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer	Phase 1/2	Recruiting	Shandong Suncadia Medicine Co., Ltd.	China
NCT06427239	Exploratory Clinical Study of HRS-4642 Combined With Adebrelimab in the Treatment of Advanced Pancreatic Ductal Adenocarcinoma (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Recruiting	Fudan University	China
NCT06474455	A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT06512051	A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT06589778	A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT06639347	A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (ClinicalTrials.gov ↗) Advanced Urothelial Carcinoma	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT06754930	A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer (NSCLC)	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06776770	A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer (ClinicalTrials.gov ↗) Gastric Cancer	Phase 1/2	Recruiting	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	China
NCT06840002	A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer (ClinicalTrials.gov ↗) Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06859775	SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer (ClinicalTrials.gov ↗) Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07059221	A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer (ClinicalTrials.gov ↗) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07105592	A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma (ClinicalTrials.gov ↗) Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Fudan University	China
NCT07229586	A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07296341	HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors (ClinicalTrials.gov ↗) Locally Advanced or Metastatic Pancreatic Cancer With	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07595172	NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer	Phase 1/2	Recruiting	West China Hospital	China
NCT06181032	A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies (ClinicalTrials.gov ↗) Biliary Tract Malignancies	Phase 1	Recruiting	First Affiliated Hospital of Fujian Medical University	China
NCT06332170	ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
NCT06336707	HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors	Phase 1	Recruiting	Hansoh BioMedical R&D Company	China
NCT06350006	SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor (ClinicalTrials.gov ↗) CLDN18.2-positive Advanced Solid Tumor	Phase 1	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07434518	A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC (ClinicalTrials.gov ↗) Small Cell Lung Cancer (SCLC)	Observational	Recruiting	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	China
NCT07640048	Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma (Icc)	Observational	Recruiting	Peking Union Medical College Hospital	China
NCT06853678	Second-line Immunotherapy for ES-SCLC (ClinicalTrials.gov ↗) Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Not applicable	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
NCT06156267	Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase EARLY_PHASE1	Not yet open	Fudan University	China
NCT07691762	A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma (ClinicalTrials.gov ↗) Hepatocellular Carcinoma	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06177522	Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, Neoadjuvant Therapy	Phase 2	Not yet open	Jinling Hospital, China	China
NCT06236997	Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer (ClinicalTrials.gov ↗) Small Cell Lung Carcinoma	Phase 2	Not yet open	Henan Cancer Hospital	China
NCT06592625	Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients (ClinicalTrials.gov ↗) Untreated Early-stage or Locally Advanced Breast Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06648525	Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC (ClinicalTrials.gov ↗) Intrahepatic Cholangiocarcinoma (Icc)	Phase 2	Not yet open	Harbin Medical University	China
NCT06684158	Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC (ClinicalTrials.gov ↗) GC/GEJC	Phase 2	Not yet open	The First Affiliated Hospital with Nanjing Medical University	China
NCT06786312	A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer (ClinicalTrials.gov ↗) Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	Fujian Cancer Hospital	China
NCT07031154	A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, Adebrelimab, Apatinib	Phase 2	Not yet open	The First Affiliated Hospital of Xiamen University	China
NCT07041437	Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer (ClinicalTrials.gov ↗) Advanced Breast Cancer	Phase 2	Not yet open	Fudan University	China
NCT07317778	Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
NCT07357532	Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD (ClinicalTrials.gov ↗) Small Cell Lung Carcinoma	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
NCT07398560	Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study (ClinicalTrials.gov ↗) Small Cell Lung Cancer	Phase 2	Not yet open	The Third Affiliated Hospital of Harbin Medical University	China
NCT07466927	Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases (ClinicalTrials.gov ↗) HER2-negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
NCT07554768	Neoadjuvant Radio-immunotherapy Versus Immunotherapy Alone for Locally Advanced HNSCC (ClinicalTrials.gov ↗) Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Chen Chunyan	China
NCT07684040	A Study of Combination Therapy in Patients With Resectable Liver Cancer (ClinicalTrials.gov ↗) Liver Cancer (Primary and Metastatic)	Phase 2	Not yet open	Affiliated Hospital of Guangdong Medical University	China
NCT07704645	The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Resectable Non-small Cell Lung Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT07770672	An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging (ClinicalTrials.gov ↗) Esophageal Cancer, ESCC	Phase 2	Not yet open	Tan Lijie	China
NCT07780721	Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer (ClinicalTrials.gov ↗) Esophageal Cancer	Phase 2	Not yet open	The Affiliated Hospital of Putian University	China
NCT07798947	A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC (ClinicalTrials.gov ↗) Limited-stage Small-cell Lung Cancer	Phase 2	Not yet open	Shanghai Hengrui Pharmaceutical Co., Ltd.	China
NCT07811375	Perioperative Adebrelimab for Locally Advanced Cervical Cancer (ClinicalTrials.gov ↗) Locally Advanced Cervical Cancer	Phase 2	Not yet open	Anhui Provincial Hospital	China
NCT07736612	A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer, RAS Mutations or Amplifications	Phase 1/2	Not yet open	Zhejiang University	China
NCT07806058	An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 1/2	Not yet open	Jiangsu HengRui Medicine Co., Ltd.	China
NCT06963502	A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer	Phase 1	Not yet open	Jiangsu Hansoh Pharmaceutical Co., Ltd.	China
NCT06773156	Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer (ClinicalTrials.gov ↗) Limited-stage Small Cell Lung Cancer (LS-SCLC)	Phase 2	By invitation	Second Affiliated Hospital of Nanchang University	China
NCT06247956	Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer (ClinicalTrials.gov ↗) Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06465563	SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer (ClinicalTrials.gov ↗) Biliary Tract Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06599216	Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer, HR+/HER2- Breast Cancer	Phase 2	Active, closed	Harbin Medical University	China
NCT06700421	Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis (ClinicalTrials.gov ↗) Unresectable Locally Advanced Non-small Cell Lung Cancer	Phase 2	Active, closed	Wei Zhou	China
NCT06766019	Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally Advanced Pancreatic Cancer (ClinicalTrials.gov ↗) Pancreatic Cancer	Phase 2	Active, closed	The First Affiliated Hospital with Nanjing Medical University	China
NCT07071714	A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
NCT06385678	A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation (ClinicalTrials.gov ↗) Advanced KRAS G12D Mutant Solid Tumors	Phase 1/2	Active, closed	Jiangsu HengRui Medicine Co., Ltd.	China
NCT07009457	A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer (ClinicalTrials.gov ↗) Widespread Small Cell Lung Cancer	Phase 1	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

104 conditions

Condition (as registered)	Trials
Pancreatic Cancer	7
Esophageal Cancer	4
Breast Cancer	4
Advanced Solid Tumors	4
Non-Small Cell Lung Cancer	3
Colorectal Cancer	3
GC/GEJC	3
Biliary Tract Cancer	3
Small Cell Lung Cancer (SCLC)	2
Esophageal Squamous Cell Carcinoma	2
Nasopharyngeal Carcinoma	2
Biliary Tract Neoplasms Immunotherapy	2
Hepatocellular Carcinoma	2
Head and Neck Squamous Cell Carcinoma	2
Advanced Urothelial Carcinoma	2
Gastric Cancer	2
HR Positive/HER2 Low Breast Cancer	2
Small Cell Lung Carcinoma	2
Intrahepatic Cholangiocarcinoma (Icc)	2
Small Cell Lung Cancer Extensive Stage	2
Resectable Non-small Cell Lung Cancer	1
Advanced Breast Cancer	1
Immunotherapy	1
Biomarkers	1
Squamous Cell Carcinoma of Head and Neck	1
Pancreatic Ductal Adenocarcinoma (PDAC)	1
Locally Advanced and Metastatic Pancreatic Cancer	1
Nasopharyngeal Cancer	1
Advanced Hepatocellular Carcinoma	1
Cervical Neoplasms	1
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	1
Non Small Cell Lung Cancer	1
Triple Negative Breast Cancer	1
ESCC	1
Adebrelimab	1
Apatinib	1
SCLC,Extensive Stage	1
Vitamin C	1
GLUT3	1
Liver Cancer (Primary and Metastatic)	1

+ 64 more conditions in the trial records above.

Trials by country register

Register	Adebrelimab trials
Clinical trials in China	110

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Adebrelimab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Adebrelimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Adebrelimab

Clinical trials of Adebrelimab

Conditions studied

Sponsors

Trials by country register

How this page is built